A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

By Mitchell Paul  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1465-1475

Informa Healthcare

Access to resources Recommend Favorite

Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age‐related macular degeneration

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 2, 2018-03 ,pp. : e201-e212

John Wiley & Sons Inc

Access to resources Recommend Favorite

Visual outcomes in patients with neovascular age‐related macular degeneration

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 2, 2018-03 ,pp. : e254-e254

John Wiley & Sons Inc

Access to resources Recommend Favorite

To dry or not too dry: should we be more tolerant of stable subretinal fluid in patients receiving anti‐vascular endothelial growth factor treatment for neovascular age‐related macular degeneration?

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 43, Iss. 8, 2015-11 ,pp. : 707-710

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?

By Neri Piergiorgio   Mariotti Cesare   Arapi Ilir   Bambini Elisa   Giovannini Alfonso  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 395-400

Informa Healthcare

Access to resources Recommend Favorite